Bayesian Capital Management’s Bionano Genomics BNGO Stock Holding History

Bayesian Capital Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-80	Closed	-$29.4K	–	710
2023 Q2	$29.4K	Buy	+80	New	+$36.1K	﹤0.01%	739
2022 Q2	–	Sell	-85	Closed	-$132K	–	796
2022 Q1	$132K	Buy	85 +54	+174%	+$72.9K	0.02%	683
2021 Q4	$55K	Buy	+31	New	+$82.9K	0.02%	351
2021 Q2	–	Sell	-103	Closed	-$499K	–	427
2021 Q1	$499K	Buy	+103	New	+$581K	0.11%	231
2020 Q3	–	Sell	-166	Closed	-$51K	–	525
2020 Q2	$51K	Buy	+166	New	+$41.7K	0.01%	488

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bayesian Capital Management's BNGO Position: Q3 2023 in Review

Bayesian Capital Management sold out of Bionano Genomics (BNGO) in Q3 2023, closing a stake of 80 shares — an estimated $29.4K sold.

Bayesian Capital Management first reported a position in BNGO in Q2 2020 and held it in 5 quarters. The position peaked at $499K in Q1 2021. 46 funds tracked by Wall St. Rank hold BNGO as of Q3 2023.

Bayesian Capital Management reported no remaining Bionano Genomics position as of Q3 2023 after selling out during the quarter.
Bayesian Capital Management sold 80 Bionano Genomics shares in Q3 2023, an estimated $29.4K.
Bayesian Capital Management first reported a position in Bionano Genomics in Q2 2020 and held it in 5 quarters.
Bayesian Capital Management's Bionano Genomics position peaked at $499K in Q1 2021.
46 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2023.

Based on Bayesian Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.